Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: A report from the Children's Oncology Group

Pediatric Blood and Cancer

Volumn 62, Issue 5, 2015, Pages 776-783

  Jakacki, Regina I ^a   Burger, Peter C ^b   Kocak, Mehmet ^c   Boyett, James M ^d   Goldwein, Joel ^e   Mehta, Minesh ^f   Packer, Roger J ^g   Tarbell, Nancy J ^h   Pollack, Ian F ⁱ  

^a MEDIMMUNE   (United States)

^b Department of Pathology ^*  (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e Perelman Center for Advanced Medicine   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Brain tumor; Pediatrics; Pineoblastoma; Prognostic factors; Radiosensitizer; Supratentorial PNET

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BRAIN VENTRICLE TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHILD; CRANIOSPINAL IRRADIATION; DOSE RESPONSE; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; ILEUS; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEUROECTODERM TUMOR; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESIS; PARESTHESIA; PERONEUS NERVE PARALYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PINEOBLASTOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SPINAL CORD METASTASIS; SPINE METASTASIS; SUPRATENTORIAL PRIMITIVE NEUROECTODERM TUMOR; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; BRAIN NEOPLASMS; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL TRIAL; MORTALITY; NEUROECTODERMAL TUMORS, PRIMITIVE; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; SUPRATENTORIAL NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBOPLATIN; CHEMORADIOTHERAPY; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM STAGING; NEUROECTODERMAL TUMORS, PRIMITIVE; PROGNOSIS; PROSPECTIVE STUDIES; SUPRATENTORIAL NEOPLASMS; SURVIVAL RATE; VINCRISTINE; YOUNG ADULT;

EID: 84925394175     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25405     Document Type: Article

References (30)

1. Gaffney CC, Sloane JP, Bradley NJ, Bloom HJ. Primitive neuroectodermal tumours of the cerebrum. Pathology and treatment J Neurooncol 1985; 3:23-33.
2. Gurney J. Monograph SP editor. Bethesda: Surveillance Research Program; 1999. pp p 51-p 63.
3. McCabe MG, Ichimura K, Liu L, Plant K, Backlund LM, Pearson DM, Collins VP. High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J Neuropathol Exp Neurol 2006; 65:549-561.
4. Pfister S, Remke M, Toedt G, Werft W, Benner A, Mendrzyk F, Wittmann A, Devens F, von Hoff K, Rutkowski S, Kulozik A, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A. Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomas. Genes Chromosomes Cancer 2007; 46:839-851.
5. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29:1408-1414.
6. Picard D, Miller S, Hawkins CE, Bouffet E, Rogers HA, Chan TS, Kim SK, Ra YS, Fangusaro J, Korshunov A, Toledano H, Nakamura H, Hayden JT, Chan J, Lafay-Cousin L, Hu P, Fan X, Muraszko KM, Pomeroy SL, Lau CC, Ng HK, Jones C, Van Meter T, Clifford SC, Eberhart C, Gajjar A, Pfister SM, Grundy RG, Huang A. Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: An integrative genomic analysis. Lancet Oncol 2012; 13:838-848.
7. Biswas S, Burke A, Cherian S, Williams D, Nicholson J, Horan G, Jefferies S, Williams M, Earl HM, Burnet NG, Hatcher H. Non-pineal supratentorial primitive neuro-ectodermal tumors (sPNET) in teenagers and young adults: Time to reconsider cisplatin based chemotherapy after cranio-spinal irradiation? Pediatr Blood Cancer 2009; 52:796-803.
8. Reddy AT, Janss AJ, Phillips PC, Weiss HL, Packer RJ. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer 2000; 88:2189-2193.
9. Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, Bayer L, LaFond D, Donahue BR, Marymont MH, Muraszko K, Langston J, Sposto R. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006; 24:4202-4208.
10. Jakacki RI, Zeltzer PM, Boyett JM, Albright AL, Allen JC, Geyer JR, Rorke LB, Stanley P, Stevens KR, Wisoff J, et al. Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children: A report of the Childrens Cancer Group. J Clin Oncol 1995; 13:1377-1383.
11. Cohen BH, Zeltzer PM, Boyett JM, Geyer JR, Allen JC, Finlay JL, McGuire-Cullen P, Milstein JM, Rorke LB, Stanley P, et al. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: A Childrens Cancer Group randomized trial. J Clin Oncol 1995; 13:1687-1696.
12. Mastrangelo R, Lasorella A, Riccardi R, Colosimo C, Iavarone A, Tornesello A, Mastrangelo S, Ausili-Cefaro G, Di Rocco C. Carboplatin in childhood medulloblastoma/PNET: Feasibility of an in vivo sensitivity test in an "up-front" study. Med Pediatr Oncol 1995; 24:188-196.
13. Gaynon PS, Ettinger LJ, Baum ES, Siegel SE, Krailo MD, Hammond GD. Carboplatin in childhood brain tumors. A Children's Cancer Study Group Phase II trial. Cancer 1990; 66:2465-2469.
14. Yang L, Douple EB, O'Hara JA, Crabtree RA, Eastman A. Enhanced radiation-induced cell killing by carboplatin in cells of repair-proficient and repair-deficient cell lines. Radiation research 1995; 144:230-236.
15. Yang LX, Douple EB, O'Hara JA, Wang HJ. Carboplatin enhances the production and persistence of radiation-induced DNA single-strand breaks. Radiation research 1995; 143:302-308.
16. Jakacki RI, Burger PC, Zhou T, Holmes EJ, Kocak M, Onar A, Goldwein J, Mehta M, Packer RJ, Tarbell N, Fitz C, Vezina G, Hilden J, Pollack IF. Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: A Children's Oncology Group Phase I/II study. J Clin Oncol 2012; 30:2648-2653.
17. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. British journal of cancer 1977; 35:1-39.
18. Massimino M, Gandola L, Spreafico F, Luksch R, Collini P, Giangaspero F, Simonetti F, Casanova M, Cefalo G, Pignoli E, Ferrari A, Terenziani M, Podda M, Meazza C, Polastri D, Poggi G, Ravagnani F, Fossati-Bellani F. Supratentorial primitive neuroectodermal tumors (S-PNET) in children: A prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy. Int J Radiat Oncol Biol Phys 2006; 64:1031-1037.
19. Pizer BL, Weston CL, Robinson KJ, Ellison DW, Ironside J, Saran F, Lashford LS, Tait D, Lucraft H, Walker DA, Bailey CC, Taylor RE. Analysis of patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study. Eur J Cancer 2006; 42:1120-1128.
20. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63:1727-1733.
21. Geyer JR, Sposto R, Jennings M, Boyett JM, Axtell RA, Breiger D, Broxson E, Donahue B, Finlay JL, Goldwein JW, Heier LA, Johnson D, Mazewski C, Miller DC, Packer R, Puccetti D, Radcliffe J, Tao ML, Shiminski-Maher T. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: A report from the Children's Cancer Group. J Clin Oncol 2005; 23:7621-7631.
22. Timmermann B, Kortmann RD, Kuhl J, Meisner C, Dieckmann K, Pietsch T, Bamberg M. Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: Results of the prospective German brain tumor trials HIT 88/89 and 91. J Clin Oncol 2002; 20:842-849.
23. Johnston DL, Keene DL, Lafay-Cousin L, Steinbok P, Sung L, Carret AS, Crooks B, Strother D, Wilson B, Odame I, Eisenstat DD, Mpofu C, Zelcer S, Huang A, Bouffet E. Supratentorial primitive neuroectodermal tumors: A Canadian pediatric brain tumor consortium report. J Neurooncol 2008; 86:101-108.
24. Tate M, Sughrue ME, Rutkowski MJ, Kane AJ, Aranda D, McClinton L, Barani IJ, Parsa AT. The long-term postsurgical prognosis of patients with pineoblastoma. Cancer 2012; 118:173-179.
25. Albright AL, Wisoff JH, Zeltzer P, Boyett J, Rorke LB, Stanley P, Geyer JR, Milstein JM. Prognostic factors in children with supratentorial (nonpineal) primitive neuroectodermal tumors. A neurosurgical perspective from the Children's Cancer Group. Pediatr Neurosurg 1995; 22:1-7.
26. Friedrich C, von Bueren AO, von Hoff K, Gerber NU, Ottensmeier H, Deinlein F, Benesch M, Kwiecien R, Pietsch T, Warmuth-Metz M, Faldum A, Kuehl J, Kortmann RD, Rutkowski S. Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy. Neuro Oncol 2013; 15:224-234.
27. Chintagumpala M, Hassall T, Palmer S, Ashley D, Wallace D, Kasow K, Merchant TE, Krasin MJ, Dauser R, Boop F, Krance R, Woo S, Cheuk R, Lau C, Gilbertson R, Gajjar A. A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro Oncol 2009; 11:33-40.
28. Burger PC. Supratentorial primitive neuroectodermal tumor (sPNET). Brain Pathol 2006; 16:86.
29. Schwalbe EC, Hayden JT, Rogers HA, Miller S, Lindsey JC, Hill RM, Nicholson SL, Kilday JP, Adamowicz-Brice M, Storer L, Jacques TS, Robson K, Lowe J, Williamson D, Grundy RG, Bailey S, Clifford SC. Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types. Acta neuropathologica 2013; 126:943-946.
30. Gessi M, von Bueren AO, Treszl A, Muhlen AZ, Hartmann W, Warmuth-Metz M, Rutkowski S, Pietsch T. MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system. Neuro Oncol 2014; 16:924-32.